ArticleDrug delivery and translational research2019
Topical delivery of 3,5,4'-trimethoxy-trans-stilbene-loaded microemulsion-based hydrogel for the treatment of osteoarthritis in a rabbit model.
Article in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Unlocking Gut Health: The Potent Role of Stilbenoids in Intestinal Homeostasis.Animals : an open access journal from MDPI · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Microemulsion-Based Keratin-Chitosan Gel for Improvement of Skin Permeation/Retention and Activity of Curcumin.Gels (Basel, Switzerland) · 2023Article
- Stilbenes, a Versatile Class of Natural Metabolites for Inflammation-An Overview.Molecules (Basel, Switzerland) · 2023Review
- Recent Developments and Current Applications of Hydrogels in Osteoarthritis.Bioengineering (Basel, Switzerland) · 2022Review
- Novel Hydrogels for Topical Applications: An Updated Comprehensive Review Based on Source.Gels (Basel, Switzerland) · 2022Review
- Therapeutic application of hydrogels for bone-related diseases.Frontiers in bioengineering and biotechnology · 2022Review
- MAPK inhibitors protect against early‑stage osteoarthritis by activating autophagy.Molecular medicine reports · 2021Article
- Percutaneous delivery of levetiracetam as an alternative to topical nonsteroidal anti-inflammatory drugs: formulation development, in vitro and in vivo characterization.Drug delivery and translational research · 2021Article
- 3,5,4'-Trimethoxy-trans-stilbene loaded microemulsion for cutaneous melanoma therapy by transdermal drug delivery.Drug delivery and translational research · 2021Article
- An impaired healing model of osteochondral defect in papain-induced arthritis.Journal of orthopaedic translation · 2021Article
- Transdermal co-delivery of glucosamine sulfate and diacerein for the induction of chondroprotection in experimental osteoarthritis.Drug delivery and translational research · 2020Article
- Eprinomectin nanoemulgel for transdermal delivery against endoparasites and ectoparasites: preparation,Drug delivery · 2019Article
- Development of a Method for the Quantification of Clotrimazole and Itraconazole and Study of Their Stability in a New Microemulsion for the Treatment of Sporotrichosis.Molecules (Basel, Switzerland) · 2019Article
- Advances in nanomedicine for the treatment of ankylosing spondylitis.International journal of nanomedicine · 2019Review
- 3,5,4'-trimethoxy-trans-stilbene loaded PEG-PE micelles for the treatment of colon cancer.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to develop a microemulsion-based hydrogel (MBH) formulation of 3,5,4'-trimethoxy-trans-stilbene (BTM) as topical delivery system for the treatment of osteoarthritis (OA). The pseudo-ternary phase diagrams were constructed to optimize the microemulsion (ME) formulation. The ME formulation containing 18.8% Cremopher EL35 (surfactant), 9.4% Transcutol HP (co-surfactant), 3.1% LABRAFIL M 1944 CS (oil), and 68.7% water was selected. The obtained BTM-loaded ME (BTM-ME) had a spherical morphology (17.5 ± 1.4 nm), with polydispersity index (PDI) value of 0.068 ± 0.016 and zeta potential of - 11.8 ± 0.5 mV, and was converted into BTM-loaded MBH (BTM-MBH) using Carbopol 940. Ex vivo skin permeation study showed that both ME and MBH formulations significantly enhanced the amount of BTM permeated. The cumulative amount of BTM permeated after 12 h (Q
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.